CCM
SPRY icon

Coldstream Capital Management’s ARS Pharmaceuticals SPRY Stock Holding History

Coldstream Capital Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-70
Closed -$881 – 3048
2025
Q1 		$881 Buy
+70
New +$842 ﹤0.01% 3218

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Coldstream Capital Management's SPRY Position: Q2 2025 in Review

Coldstream Capital Management sold out of ARS Pharmaceuticals (SPRY) in Q2 2025, closing a stake of 70 shares — an estimated $881 sold.

Coldstream Capital Management first reported a position in SPRY in Q1 2025 and held it in 1 quarter. The position peaked at $881 in Q1 2025. 187 funds tracked by Wall St. Rank hold SPRY as of Q2 2025.

  • Coldstream Capital Management reported no remaining ARS Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 70 ARS Pharmaceuticals shares in Q2 2025, an estimated $881.
  • Coldstream Capital Management first reported a position in ARS Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Coldstream Capital Management's ARS Pharmaceuticals position peaked at $881 in Q1 2025.
  • 187 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.